Study to Assess Resource Utilization and Quality of Life of Patients With RRMS Treated With Tecfidera in Greece

The study will take place in Greece. Investigators will participate from a broad geographical distribution in order to ensure a proper representation from all areas of Greece. Investigator's decision to prescribe DMF (Tecfidera®) (according to the indication for treatment as defined in the summary of product characteristics, SmPC and the current clinical practice), should precede entry into the study.

Inclusion criteria

• Persons aged 18-65 years.
• Patients with a confirmed diagnosis of RRMS.
• Patients for whom the decision to prescribe therapy with Tecfidera®, according to the locally approved product's summary of product characteristics (SmPC) has already been taken prior to their enrolment in the study. The assignment of a patient to this therapeutic strategy is not decided in advance, but falls within current practice, while the prescription of Tecfidera® is clearly separated from the physician's decision to include the patient in the current study.
• Patients must have signed an informed consent document.
• Patients must be able to read, understand and complete the study specific questionnaire.

Exclusion criteria

• Patients having other forms of MS, like Clinically Isolated Syndrome (CIS) or progressive forms.
• Patients who have initiated treatment with Tecfidera® more than 7 days before study enrolment or have received DMF at any different time prior to this period.
• Patients that meet any of the contraindications to the administration of the study drug according to the approved SmPC.
• Receipt of any investigational agent within 30 days or 5 half-lives of the investigational agent (whichever is longer) before the commencement of therapy with Tecfidera®.